Find Specific Jobs
German-American cousins Charles Pfizer and Charles Erhart began Pfizer in 1849.
Started by immigrant cousins Charles Pfizer and Charles Erhart in 1849, Pfizer helped usher in the age of modern medicine by answering the United States government's call, during World War II, to devise a process for mass-producing penicillin.
Once in the states, they opened a chemical firm in Brooklyn in 1849, Charles Pfizer & Company.
The subsequent demand for disinfectants, preservatives, and painkillers during the American Civil War (1861–65) doubled the company’s revenue and allowed for its expansion.
1866 Parke-Davis is founded in Detroit by Hervey C. Parke and George S. Davis.
As the company expanded, the headquarters moved to Manhattan in 1868.
The manufacturing of straight razors began in 1877.
1877 Wilkinson Sword begins making straight razors.
In 1879 the company's other founder, Jordan Lambert, developed the first surgical antiseptic, which saved the lives of many patients undergoing medical operations.
Lawrence sold his formula in 1881 to Jordan Wheat Lambert, who founded the Lambert Pharmacal Company to make and sell Listerine.
In 1881, Pfizer moved its administrative headquarters to 81 Maiden Lane in Manhattan, presaging the company's expansion to Chicago, Illinois a year later.
A separate warehouse opened in Chicago in 1882.
In 1886 he formed William R. Warner & Company and began making drugs.
American Chicle had been formed in 1899 through the merger of several major United States gum producers.
In 1900 the company was incorporated in New Jersey as Charles Pfizer & Company Inc.
In 1905 Pfizer’s youngest son, Emile, was appointed president of the company; Charles Pfizer died the following year.
Pfizer spent summers in similarly exclusive Newport, Rhode Island, where he died in 1906.
By 1906, sales exceeded $3 million.
In 1908, several years after Warner’s death, the company was acquired by Gustavus A. Pfeiffer & Company, a patent medicine company from St Louis.
By 1914 the Italian imports stopped entirely, as the United States engaged in war in Europe, and Pfizer found other sources, although they were limited.
Pfeiffer retained the Warner company name, moved its headquarters to New York, and began a series of acquisitions that included Richard Hudnut Company, a cosmetics firm acquired in 1916, and the DuBarry cosmetic company.
Chemist James Currie joined Pfizer in 1917 and quickly applied his expertise in fermentation.
The product became widely popular, particularly under the advertising strategy of Gordon Seagrove, who joined Lambert in 1926 after leaving his job as a calliope player in the circus.
Encouraged by this success, Pfizer pushes ahead in 1938 with production of vitamin B-2, or riboflavin, and eventually develops a vitamin mix that includes riboflavin, thiamin, niacin, and iron.
On June 2, 1942, the company incorporated in Delaware.
By 1942 Pfizer divided the first flask of penicillin into vials for the medical departments of the Army and Navy; this flask was valued at $150,000.
In 1943 John L. Smith, Pfizer president, and John McKeen, against the explicit regulations of the federal government, supplied penicillin to a doctor at the Brooklyn Jewish Hospital.
Mass production began in 1944, when Pfizer penicillin arrived with the Allied forces on the beaches of Normandy on D-Day.
1944 Pfizer begins mass production of penicillin, primarily for the war effort.
Elmer Holmes Bobst arrived at Warner in 1945, already a veteran executive of the pharmaceutical industry and a multimillionaire.
In 1946 sales already had reached $43 million.
The company has a state-of-the-art and manufacturing facility in Goa that produces more than a billion tablets annually.Pfizer came to the Indian market in 21st November of the year 1950 through a company named Dumex Limited.
1950 Pfizer launches Terramycin, an antibiotic; Warner & Co. is renamed Warner-Hudnut, Inc.
In 1952, Bobst made his first major acquisition, purchasing New Jersey Chilcott Laboratories, Inc.
Established in 1953, the Pfizer Foundation is Pfizer's charitable organization.
Warner-Lambert introduced Rolaids in 1954 with a single flavor, peppermint.
Warner-Lambert Company was the product of the 1955 merger of Warner-Hudnut, Inc. and the Lambert Pharmacal Company.
By 1955, Bobst's holdings were worth more than $3 million.
When Warner and Lambert merged in 1955 to form Warner-Lambert Company, former governor Alfred Driscoll was named president of the new company.
The new company quickly outgrew its New York headquarters and so relocated to Morris Plains, New Jersey, a suburb of New York City, in 1956.
Warner-Lambert acquired Emerson Drug, maker of Bromo-Seltzer, in 1956.
In 1959, the company established an animal health division with a 700-acre (2.8 km) farm and research facility in Terre Haute, Indiana.
In 1960 Pfizer established a large and modern plant at Thane near Mumbai which housed manufacturing quality control and product research facilities.
In 1964 sales did surpass $480 million, but the following year Powers replaced McKeen as chief executive officer and president and inherited a company with almost half its sales generated from foreign markets and wide product diversification from 38 subsidiaries.
In 1965, John Powers, Jr. became chief executive officer of the company, succeeding John McKeen.
By 1966, however, when an estimated 56 percent of the 3.1 million people afflicted by heart disease used Peritrate, the government, under the directive of the FDA, seized a shipment of the drug, bringing charges against the company’s unapproved advocacy of an even wider usage for the drug.
John J. Powers, Jr.,is named president and CEO. John McKeen, whom he succeeds, remains chairman of the board, a position he holds until 1968, when Powers assumes full leadership of the company.
A large research and development laboratory of the company at Thane was commissioned in the year 1969.
On November 12, 1970, the Justice Department announced that it would not challenge the merger despite the Antitrust Division’s recommendation to the contrary.
In 1970 the company changed its name to the more modern-sounding Pfizer Inc.
Warner-Lambert also acquired Parke, Davis & Co. in 1970.
In the early 1970’s Edmund Pratt Jr. stepped in as company chairman and Gerald Laubach took over as Pfizer president.
The company veteran, who joined Pfizer in 1971, was faced with the challenges of integrating the staffs and cultures of Pfizer and Warner-Lambert, healing whatever wounds might be left over from the bruising takeover battle, and restoring investor confidence in the company’s product pipeline.
In 1972, Edmund T. Pratt Jr. became chief executive officer of the company, succeeding John Powers, Jr.
Concurrently, Listerine continued to increase in popularity under its new ownership; by 1975, the oral antiseptic held a sizable portion of the $300 million market.
By 1975, the Federal Trade Commission (FTC) had begun to investigate the Listerine advertisements.
By 1976, however, the FTC ordered the company to sell several units of its Parke, Davis subsidiary that produced specified drugs.
In 1976, Warner-Lambert disclosed figures to the Securities and Exchange Commission (SEC) concerning illegal payments abroad, announcing that more than $2.2 million "in questionable payments" had been uncovered in 14 of the 140 countries in which Warner-Lambert conducted business.
Mines, Samuel, Pfizer: An Informal History, New York: Pfizer, 1978.
In 1978, Warner-Lambert purchased Entenmann’s Bakery for $243 million in cash.
Read began his career with Pfizer in 1978 as an operational auditor.
Profit margins were off by 40 percent in 1979, the majority of revenues came from the sale of consumer goods, and the company was considered a potential takeover candidate.
Davenport, Caroline H., "Glowing Prospects: New Products Will Keep Pfizer Growing at a Healthy Clip," Barron's, December 22, 1980.
Lubriderm was first marketed to the general public in 1980.
By 1980 Pfizer was one of two United States companies among the top ten pharmaceutical companies in Europe, and the largest foreign health care and agricultural product manufacturer in Asia.
Restructuring and Refocusing on Core Areas: 1980-99
In 1980, Pfizer launched Feldene (piroxicam), a prescription anti-inflammatory medication that became Pfizer's first product to reach $1 billion in revenue.
In 1981, the company received approval for Diflucan (fluconazole), the first oral treatment for severe fungal infections including candidiasis, blastomycosis, coccidiodomycosis, cryptococcosis, histoplasmosis, dermatophytosis, and pityriasis versicolor.
Despite its improved financial condition, Warner-Lambert came under criticism, particularly for its 1982 purchase of IMED Corp., a small hospital supply manufacturer.
As Entenmann’s profits continued to slip, Warner-Lambert sold the bakery to General Foods for $315 million in 1982.
Agouron had been founded in 1984 by several University of California at San Diego scientists who pioneered in computer-aided drug design.
Seldane had been launched in 1985 and was one of the first major prescription drugs promoted with direct-to-consumer advertising.
In 1986, Warner-Lambert sold IMED and some of its affiliates to the Henley Group, Inc. for $163.5 million.
In 1986, Pfizer acquired the worldwide rights to Zithromax (azithromycin), a macrolide antibiotic that is recommended by the Infectious Disease Society of America as a first line treatment for certain cases of community-acquired pneumonia, from Pliva.
In 1988 it extended its line to include assorted fruit flavors, but from the beginning its emphasis was on scientific claims rather than on taste.
Recently, Pfizer has reported $4 billion in sales, projected $500 million for research and development by 1988, and commanded one of the largest overseas operations in the industry.
Procardia XL was launched in 1989, and Diflucan, an antifungal agent, received Food and Drug Administration (FDA) approval.
Sales of Pfizer’s newest products accounted for 30 percent of all pharmaceutical sales, up from 13 percent in 1989.
In 1989, Pfizer scientists Peter Dunn and Albert Wood created Viagra (sildenafil) for treating high blood pressure and angina, a chest pain associated with coronary artery disease.
Net sales in 1990 reached $6.4 billion.
Pfizer International launched 37 new products worldwide in 1990.
In 1990 Gillette introduced the Sensor, a high-tech, premium-priced razor with two independently suspended blades that were designed to give a "contoured" shave.
In anticipation of these potentially adverse market forces, a new chairperson and CEO, Melvin R. Goodes, announced yet another reorganization of Warner-Lambert late in 1991.
Schick saw the wisdom of selling an appealing, premium permanent razor, and in 1991 the company came out with the Tracer, a variation on the Sensor and an attempt to capture some of Gillette's market.
In 1991, it was patented in the United Kingdom as a heart medication.
In 1991, William C. Steere, Jr. became chief executive officer of the company, succeeding Edmund T. Pratt Jr.
In 1991 Pfizer also began marketing Zoloft (sertraline), an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class developed nine years earlier by Pfizer chemists Kenneth Koe and Willard Welch.
Also in 1992, the company introduced Veri-Lo fat extenders for use in low-fat salad dressings, mayonnaise and sauces.
Net sales in 1992 were $7.2 billion, with a net income of $811 million, and research and development expenses hit $863 million.
Sixty additional launches were slated for 1992.
“Pfizer Shareholders are Told Company is Well-Positioned for Growth in Changing Pharmaceuticals Environment,” PR Newswire, April 22, 1993.
Another development in 1993 was the acquisition of Wilkinson Sword, a maker of shaving products and toiletries and a business that fit well alongside Schick.
Sales, however, quickly declined in 1993; Warner-Lambert’s late entry into the segment, chronic product shortages, a lower than expected success rate, side effects, and, especially, reports that some users had suffered heart attacks, all led to declines in sales.
In 1993, the company became the first to win approval from the FDA for a drug (Cognex) that retarded the progression of Alzheimer’s disease.
Pfizer also vowed not to raise prices on any single product by more than 4.5 percent in 1993.
In 1994 Gillette introduced the Sensor Excel, which had a rubber strip and other innovations that promised a closer, safer shave.
The company had invigorated the $158 million liquid body cleanser market with the introduction of Jergens Refreshing Body Shampoo in 1994.
"Lubriderm Gator Is Back." Advertising Age, October 18, 1995.
"Jergens Introduces Shower Lotion." Advertising Age, November 15, 1995.
The operations started with the hiring of a statistician in 1995.
Development Operations (Dev Ops) India formerly a part of the Clinical Research Division was established in 1995.
By 1995, in fact, the R&D budget hit $1.3 billion.
For the Tracer FX launch in 1995, Schick ran the Magali ads.
A decade later, not only Rolaids but all traditional antacids were reeling from the introduction of entirely new competitors: H2 blockers, led by SmithKline Beecham's Tagamet HB. As Leon Jaroff of Time wrote in 1995 in describing Tagamet's forceful marketing, "Suddenly a roar issues from the TV set.
1995 Pfizer acquires the animal health unit of SmithKline Beecham.
"H2 Blockers' US Sales Boom Set to Slow?" Marketletter, October 21, 1996.
Pfizer had acquired the animal healthcare operations of SmithKline Beecham in the year 1996.
That segment of the company had grown 3 percent in 1996.
The company increased media spending for Rolaids by $6 million, to $20 million, and as Wilke reported, "look[ed] to the brand's past for its first new campaign since 1996." Once again, Rolaids advertising would contain the tag line "R-o-l-a-i-d-s spells relief" and would emphasize sports.
"Warner-Lambert Reports Fourth Quarter, Full-Year Sales and Earnings." PRNewswire, January 28, 1997.
The first treatment not requiring injection—a urethral suppository named Muse, manufactured by VIVUS, Inc.—debuted in January 1997 and generated 17,000 prescriptions a week as well as a rapid increase in the price of VIVUS stock in its first year.
"Warner-Lambert's First Schick Master Brand Image Campaign Breaking in June." Rose Sheet, June 23, 1997.
Sloan, Pat. "$48 Mil Effort for Nivea as Revlon Readies Rival." Advertising Age, June 16, 1997.
Claritin's extensive promotional program included the "Blue Skies" campaign of print advertisements and television commercials, introduced in August 1997.
In August 1997, when the Food and Drug Administration revised the guidelines that governed television commercials for prescription drugs, pharmaceutical companies were allowed to expand the content of their advertisements.
Ironically, the 33-year-old Farley's own unhealthy lifestyle caught up with him in December 1997, when he was found dead in his Chicago apartment.
A dedicated Informatics group of the company for all technical and applications support has been available since 1997.
In 1997 Beiersdorf ran a $20 million campaign on television and in print media with the tag line "Nivea Brings Your Face to Life.
Warner-Lambert reported record income in 1997, including a 1 percent increase in its $1.4-billion United States consumer health care operations.
1997 Warner-Lambert launches Lipitor through a marketing alliance with Pfizer.
"J&J/Merck Pepcid AC First Chewable H2 Is Latest Twist in Stomach Remedy Market." Tan Sheet, January 12, 1998.
In March 1998 Pfizer Inc., the world's largest research-based pharmaceutical company, won FDA approval of its anti-impotency drug, Viagra.
In May 1998 Zyrtec became the first leading prescription antihistamine approved by the United States Food and Drug Administration for use by children two to six years old.
The consumer campaign broke in late June 1998 with the reserved, relationship-centered "Let the Dance Begin" print ads as well as educational spots, which appeared in magazines including Newsweek, Time, Life, and United States News & World Report.
In September 1998 a nationwide survey of 2,000 physicians found that when patients asked for a drug by its brand name, they most often requested an allergy medication.
The pace of work of Clinical Research Division was picked up in 1998 and this was followed by a substantial growth in terms of activities and resources especially in data management.
NOTE: Since the initial appearance of this essay in the 1998 edition of Major Marketing Campaigns Annual, Warner-Lambert was acquired by Pfizer Inc.
Then in March 1999 the Dole spot marked Viagra's television launch.
The Rezulin setback and the lack of any blockbusters in the pipeline that were close to market provided the impetus for Warner-Lambert’s acquisition of Agouron Pharmaceuticals, Inc. for about $2.1 billion in stock in May 1999.
Goodes retired from his position as CEO and chairman of Warner-Lambert in May 1999, with the company’s president, Lodewijk J.R. de Vink, taking on Goodes’s titles as well.
It was with this somewhat shaky product pipeline as a backdrop that Pfizer entered into a battle for control of Warner-Lambert in late 1999, a battle that Pfizer won early the following year.
The results of the campaign had not materialized by mid-1999, and the lack of reporting on the subject made it difficult to discern the future direction of Rolaids.
The cost of the 1999 television campaign was estimated at $35 million, and the TV spots were supported by the ongoing print segment of the campaign.
The introduction of the original, 7-valent version of the vaccine, developed by Wyeth in February 2000, led to a 75% reduction in the incidence of invasive pneumococcal infections among children under age 5 in the United States.
In June 2000, Pfizer acquired Warner-Lambert outright for $116 billion.
Langreth, Robert. "Hard Sell." Forbes, October 16, 2000.
In 2000 Pfizer began to phase out the Dole work as well as the branded spots, in favor of a "Faces of ED" theme, which featured men from a range of age groups.
William C. Steere, Jr. announces his retirement as CEO on January 1, 2001, and steps down as Chairman of the Board in April, following the company's annual meeting.
Two major product launches were anticipated to occur in 2001: Zeldox, an antipsychotic drug, and Relpax, a migraine treatment.
Sales leapt 28 percent in 2001, from $5.0 billion to $6.4 billion.
The foundation's mission is to "promote health care and education, to nurture innovation, and to support the community involvement of Pfizer people." In 2001 the Pfizer Foundation donated more than $400 million in products and money to organizations and people in the United States.
In 2001, Henry McKinnell became chief executive officer of the company, replacing William C. Steere, Jr.
"significant developments, pfizer inc." market guide, 25 march 2002.
"pfizer profits surge on strong sales." reuters, 17 april 2002.
"Cadbury-Schweppes Snaps Up Adams from Pfizer," Investors Chronicle, December 19, 2002.
The operational merger between the company and Parke-Davis had been completed in the year 2002.
Express Pharma Biz Award came to company's hands in the year 2002 for overall performance.
Although Pfizer anticipated continued growth, shares in 2002 were on a slight downtrend and, at the end of the first quarter, were trading at $42.44 per share, with resistance at $42.50 per share.
2002 Pfizer's Lipitor ranks as the best-selling drug in the world.
On April 16, 2003 Pfizer Inc and Pharmacia Corporation combine operations, bringing together two of the world´s fastest-growing and most innovative companies.
In mid 2003 the Mumbai group was aligned under Dev Ops Europe to emphasize its focus on operations and facilitate more interactions and project engagements from all sites.
As such it established a virtual sales monopoly in its category beginning at the time of its launch, but in late 2003 two new rivals touting advantages over Viagra entered the market behind high-profile launch campaigns.
After winning FDA approval for Cialis in late 2003, Eli Lilly and Company partnered with ICOS Corp. to comarket the drug.
In 2003, the first eighteen Global Health Fellows are sent into the field.
Pfizer and Pharmacia Merger: 2003
2003 Pfizer merges with Pharmacia Corp., making it the largest drugmaker in the world.
In 2003, Pfizer merged with Pharmacia, and in the process acquired Searle and SUGEN. Searle had developed Flagyl (metronidazole), a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa.
By April 2004, over half a million seniors enrolled in the program and nearly five million prescriptions were filled.
The drug generated $3.3 billion in revenue in 2004, but hopes for increased sales were dashed when the FDA pulled Merck's drug Vioxx, also a Cox-2 drug, from the market in October 2004.
In 2005, the year before it became a generic drug, sales were over $3 billion and over 100 million people had been treated with the drug.
In July 2006, Jeff Kindler was named chief executive officer of the company, replacing Henry McKinnell.
In October 2006, the company announced it would acquire PowerMed.
On December 3, 2006, Pfizer ceased development of torcetrapib, a drug that increases production of HDL, or "good cholesterol", which reduces LDL thought to be correlated to heart disease.
The patent for Zoloft expired in the summer of 2006.
Kindler succeeds Hank McKinnell, who will remain Chairman of the Board until his retirement in February, 2007.
In July 2008, Pfizer announced 275 job cuts at its manufacturing facility in Kalamazoo, Michigan.
Drugwatch.com has provided reliable, trusted information about medications, medical devices and general health since 2008.
Worldwide sales of inhaled insulin products were expected to achieve sales of $4.8 billion by 2010, and Pfizer hoped Exubera would lead the way.
In 2010, Ian Read was named chief executive officer of the company.
In February 2011, Pfizer announced the closure of its UK research and development facility (formerly also a manufacturing plant) in Sandwich, Kent, which at the time employed 2,400 people.
In March 2011, Pfizer acquired King Pharmaceuticals for $3.6 billion in cash.
In July 2011 Pfizer Inc USA. the Ultimate Holding Company of Pfizer Ltd announced that it was reviewing strategic alternatives for its global animal health business.
The Board of Directors of Pfizer Ltd at its meeting held on 8 November 2012 approved the sale of its animal health business to Pfizer Animal Health India Limited a 100% indirect subsidiary of Pfizer Inc.
By 2012, Pfizer settled most of the claims for more than $1 billion.
On February 1, 2013, Zoetis, the Agriculture Division of Pfizer and later Pfizer Animal Health, became a public company via an initial public offering, raising $2.2 billion.
In 2013, Pfizer announced it was recalling five lots of Prempro.
In 2013, the company set aside about $288 million to resolve these cases.
Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal health business to Zoetis.
In September 2014, the company acquired Innopharma for $225 million, plus up to $135 million in milestone payments, in a deal that expanded Pfizer's range of generic and injectable drugs.
The Company has in place a robust business continuity plan which will ensure that its medicines are available to the patients at all times.On 1 December 2014 Pfizer Limited announced the completion of the merger with Wyeth Limited.
In May 2015, Pfizer and a Bar-Ilan University laboratory announced a partnership based on the development of medical DNA nanotechnology.
In September 2015, Pfizer acquired Hospira for $17 billion, including the assumption of debt.
Corex recorded sale of Rs 176 crore for the nine months period ended 31 December 2015.
However, in April 2016 the United States government introduced regulations to prevent such tax-inversion deals, and shortly thereafter the merger was called off.
In August 2016, the company made a $40 million bid for the assets of BIND Therapeutics, which was in bankruptcy.
In September 2016, the company acquired cancer drug-maker Medivation for $14 billion.
The company will be launching a series of products as line extensions under the Corex brand name starting with the first launch in December 2016 and subsequent launches over the next year.
CBS News. (2017, February 23). Heartburn meds associated with increased risk of kidney damage, study finds.
On 31 May 2017 Pfizer Limited (India) informed the stock exchanges that it has entered into an agreement with AstraZeneca AB Sweden to acquire the brand 'Neksium' in India for a value of Rs 75 crore.
USA had announced on October 10 2017 that it was considering a review of strategic alternatives for its Global Consumer Healthcare business.
The company is a subsidiary of Pfizer Inc. the world's premiere biopharmaceutical corporation with annual revenues of $52.5 billion in 2017.
In January 2018, Pfizer announced that it would end its work on research into treatments for Alzheimer's disease and Parkinsonism (a symptom of Parkinson's disease and other conditions). The company said about 300 researchers would lose their jobs.
In August 2018, Pfizer signed an agreement with BioNTech to conduct joint research and development activities regarding mRNA-based influenza vaccines.
USA had announced on July 29 2019 that it had entered into a definitive agreement to combine its Upjohn Business which consists off-patented branded and generic established medicines with Mylan N.V. thereby creating a new global pharmaceutical Company.
In July 2019, the company acquired Therachon for up to $810 million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as achondroplasia.
In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a joint venture owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a public company.
Pfizer is a publicly-traded global pharmaceutical company headquartered in New York City. Its revenues reached $51.8 billion in 2019.
In March 2020, as the scale of the COVID-19 pandemic became apparent, Pfizer partnered with BioNTech to study and develop COVID-19 mRNA vaccine candidates.
In May 2020, Pfizer began testing four different COVID-19 vaccine variations.
In November 2020, the drugmaker announced that data from Phase 3 clinical trials had shown the vaccine was safe and effective with an efficacy of 95 percent.
On November 9, 2020, Pfizer announced that BioNTech's COVID-19 vaccine, tested on 43,500 people, was found to be 90% effective at preventing symptomatic COVID-19.
In December 2020, the company became the first to receive an emergency use authorization from the FDA for a COVID-19 vaccine.
The patents for Viagra expired in 2020.
23, 2021, the Food and Drug Administration approved Comirnaty, Pfizer's COVID-19 vaccine. It was the second-largest pharmaceutical company by revenue in 2020.
On January 5, 2021, Pfizer introduced a new logo.
"Pfizer Inc. ." International Directory of Company Histories. . Retrieved April 15, 2021 from Encyclopedia.com: https://www.encyclopedia.com/books/politics-and-business-magazines/pfizer-inc-0
As of early May 2021, Pfizer and BioNTech had manufactured at least 430 million vaccine doses, which have been distributed to 91 countries and territories.
On 2 November 2021, The BMJ published an article after obtaining information from a whistleblower from the Ventavia Research Group.
18, 2021 announcing that a third booster shot for Americans who received the Pfizer vaccine will be available beginning the week of Sept.
The companies have said they expect to manufacture nearly 3 billion total vaccine doses in 2021.
Glance user base grows by 30% YoY to reach 183 million in Q1 2022
|Company Name||Founded Date||Revenue||Employee Size||Job Openings|
|Johnson & Johnson||1886||$94.9B||134,500||5,454|
|Eli Lilly and Company||1876||$28.5B||33,625||169|
|The Dow Chemical Company||1897||$56.9B||54,000||66|
Zippia gives an in-depth look into the details of Pfizer, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Pfizer. The employee data is based on information from people who have self-reported their past or current employments at Pfizer. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Pfizer. The data presented on this page does not represent the view of Pfizer and its employees or that of Zippia.
Pfizer may also be known as or be related to Pfizer, Pfizer Inc, Pfizer Inc. and Pfizer, Inc.